This article presents background information and highlights key findings from a managed care perspective related to enlarged prostate (EP) in Medicare-eligible patients. This article does not provide ...

Prostate cancer remains a significant public health problem. The current approach with prostate-specific antigen (PSA)-based screening has questionable effects on prostate cancer–specific mortality ...

Compared to placebo treatment, taking 5-alpha-reductase inhibitors (5-ARIs) can reduce a man's risk of being diagnosed with prostate cancer from around 5--9 percent to around 4-6 percent during up to ...

Dublin, April 15, 2024 (GLOBE NEWSWIRE) -- The "5-Alpha Reductase Deficiency Global Market Report 2024" has been added to ResearchAndMarkets.com's offering. The 5-alpha reductase deficiency market ...

Objective: The purpose of this study was to examine the rates of acute urinary retention (AUR) and surgery after initiating 5-alpha reductase inhibitor (5ARI) therapy and to compare the 2 currently ...

Use of elevated baseline IL-8, CCL-2, and TNFα to predict for shorter overall survival (OS) in men with metastatic prostate cancer initiating androgen-deprivation therapy (ADT). Background: Active ...

The FDA has notified healthcare professionals that the Warnings and Precautions section of the labeling for the class of 5-alpha reductase inhibitors has been revised to include new safety information ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio While 5-alpha-reductase inhibitor use did ...

Compared to placebo treatment, taking 5-alpha-reductase inhibitors (5-ARIs) can reduce a man’s risk of being diagnosed with prostate cancer from around 5–9% to around 4-6% during up to 7 years of ...